Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2350 - A large prospective cohort study of the clinical features of advanced lung cancer harboring HER2 aberrations (HER2-CS STUDY).

Date

09 Sep 2017

Session

Poster display session

Topics

Cancers in Adolescents and Young Adults (AYA);  Non-Small Cell Lung Cancer

Presenters

Tae Tanaka

Citation

Annals of Oncology (2017) 28 (suppl_5): v460-v496. 10.1093/annonc/mdx380

Authors

T. Tanaka1, H. Yoshioka1, A. Bessho2, N. Ishikawa3, M. Yamasaki4, T. Shibayama5, K. Aoe6, T. Kozuki7, N. Fujimoto8, K. Genba9, Y. Ueda10, M. Inoue11, T. Murakami12, S. Kuyama13, H. Kawai14, K. Fujitaka15, K. Inoue16, M. Takata17, H. Yanai18, K. Kiura19

Author affiliations

  • 1 Respiratory Medicine, Kurashiki Central Hospital, 710-8602 - Kurashiki/JP
  • 2 Respiratory Medicine, Japanese Red Cross Okayama Hospital, 700-0491 - Okayama/JP
  • 3 Respiratory Medicine, Hiroshima Prefectural Hospital, Hiroshima/JP
  • 4 Respiratory Medicine, Hiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital, Hiroshima/JP
  • 5 Respiratory Medicine, NHO Okayama Medical Center, Okayama/JP
  • 6 Respiratory Medicine, Yamaguchi-Ube Medical Center, Ube/JP
  • 7 Respiratory Medicine, NHO Shikoku Cancer Center, Matsuyama/JP
  • 8 Medical Oncology, Okayama Rosai Hospital, Okayama/JP
  • 9 Medical Oncology, Chugoku Central Hospital, Fukuyama/JP
  • 10 Respiratory Medicine, Kagawa Prefectural Central Hospital, Takamatsu/JP
  • 11 Thoracic Surgery, Shimonoseki City Hospital, Shimonoseki/JP
  • 12 Respiratory Medicine, Japanese Red Cross Society Himeji Hospital, Himeji/JP
  • 13 Respiratory Medicine, Iwakuni Medical Center, Iwakuni/JP
  • 14 Respiratory Medicine, Okayama Saiseikai General Hospital, Okayama/JP
  • 15 Respiratory Internal Medicine, Hiroshima University, 734-8551 - Hiroshima/JP
  • 16 Respiratory Medicine, Ehime Prefectural Central Hospital, Matsuyama/JP
  • 17 Department Of Late Effects Studies, Radiation Biology Center, Kyoto University, Kyoto/JP
  • 18 Diagnostic Pathology, Okayama University Hospital, Okayama/JP
  • 19 Respiratory Medicine, Okayama University Hospital, Okayama/JP
More

Resources

Abstract 2350

Background

HER2 is a potential driver oncogene. HER2-targeted precision therapy has been tested in NSCLC. However, the demographics of HER2-positive NSCLC have not been defined systematically.

Methods

Pts with advanced NSCLC were registered. HER2-IHC and FISH assays were performed with commercial kits. HER2 mutations were identified by the direct sequencing. The aim of this study was to clarify the frequency, characteristics and outcome of HER2-positive NSCLC.

Results

Of 1,126 tumors screened (Table A), 34 (3.0%) were IHC3+, and 34 (3.0%) were IHC2+/FISH+. Among the 724 EGFR wild-type tumors, 21 (2.9%) were HER2-mutant tumors, including A775_G776insYVMA (n = 15). Interestingly, the IHC3+ tumors and mutant tumors were entirely exclusive. Female pts had HER2 mutant tumors more frequently, while IHC/FISH+ tumors were detected more often in males (Table B). HER2-positive tumors had similar survival outcome to triple negative tumors, but significantly worse prognoses than EGFR-mutant and ALK-positive tumors (p 

Conclusions

This is the first prospective study showing a small fraction of NSCLC possessed HER2 aberrations. HER2-positive tumors had relatively poor prognosis. NSCLCs with HER2 IHC3+ and mutation seemed to be distinct subsets.

Clinical trial identification

UMIN registration number 000017003

Legal entity responsible for the study

HER2-CS Network

Funding

Japan Agency for Medical Research and Development

Disclosure

H. Yoshioka: Honoraria: Eli Lilly, Chugai Pharma., Boehringer Ingelheim, Taiho Pharmaceutical, Pfizer, AstraZeneca, Bristol-Myers Squibb, Ono Pharmaceutical, Takeda Pharma. T. Shibayama: Honoraria: Meiji Seika Pharma Co., Ltd. Astra Zeneca K.K. Boehringer Ingelheim Pharmaceuticals, Inc. Eli Lilly Japan K.K. K. Aoe: Eli Lilly, Astrazeneca, BMS, Ono Pharmaceutical Co., Ltd. T. Kozuki: Honoraria: Chugai Pharma., AstraZeneca, Eli lilly Japan, Pfizer, Ono Pharm., Bristol-Myers Squibb, Kyowa-Hakko Kirin, Boehringer Ingelheim. N. Fujimoto: Honoraria: Kissei Co. Ltd. S. Kuyama: Honoraria: Chugai Pharma., AstraZeneca, Pfizer, Ono Pharm., Boehringer Ingelheim, Meiji Seika Pharma. H. Yanai: Honoraria: Bayer Yakuhin, Ltd, Janssen Pharmaceutical K.K., Kyowa Hakko Kirin Co., Ltd., Becton, Dickinson and Company, Fujiyakuhin Co., Ltd. K. Kiura: Honoraria: Chugai Pharmaceutical Co., Ltd. Pfizer Japan Inc. Novartis Pharma K.K. Taiho Pharmceutical Co., Ltd. Eli Lilly Japan K.K. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.